Wang, Xiaoxing
Dowty, Martin E.
Wouters, Ann
Tatulych, Svitlana
Connell, Carol A.
Le, Vu H.
Tripathy, Sakambari
O’Gorman, Melissa T.
Winton, Jennifer A.
Yin, Natalie
Valdez, Hernan
Malhotra, Bimal K.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
https://doi.org/10.1007/s13318-021-00745-6
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
https://doi.org/10.1007/s13318-021-00745-6
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
https://doi.org/10.1007/s13318-021-00745-6
Funding for this research was provided by:
Pfizer
Article History
Accepted: 8 December 2021
First Online: 28 February 2022
Declarations
:
: These trials were sponsored by Pfizer Inc.
: All authors are employees and stockholders of Pfizer Inc.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See ExternalRef removed for more information.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by XW, MO, AW, JAW, and ST. Bioanalytical data preparation and interpretation were performed by VL and ST. VL performed all statistical analyses of pharmacokinetics data. AW and ST contributed to study safety. The first draft of the manuscript was written by XW; all authors critically reviewed the drafts and approved the final manuscript.
: This research was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The final protocol, any amendments, and informed consent documentation were reviewed and approved by the Independent Ethics Committee at the investigational center participating in the study.
: Written informed consent was obtained from all participants prior to enrollment.
: Not applicable.